Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q7L8A9
UPID:
VASH1_HUMAN
Alternative names:
Tubulin carboxypeptidase 1; Tyrosine carboxypeptidase 1; Vasohibin-1
Alternative UPACC:
Q7L8A9; Q96H02; Q9UBF4; Q9Y629
Background:
Tubulinyl-Tyr carboxypeptidase 1, also known as Vasohibin-1, plays a pivotal role in microtubule dynamics by removing the C-terminal tyrosine residue of alpha-tubulin. This action is crucial for spindle function and accurate chromosome segregation during mitosis, highlighting its importance in cell division and genetic stability.
Therapeutic significance:
Understanding the role of Tubulinyl-Tyr carboxypeptidase 1 could open doors to potential therapeutic strategies. Its unique function in regulating mitotic spindle length and positioning, coupled with its selective inhibition of endothelial cell migration and angiogenesis, positions it as a target of interest in cancer research and treatment of angiogenesis-related diseases.